HRTX Earning Date, Earning Analysis and Earning Prediction

Quarterly Results

HRTX Earnings Forecast

Looking ahead, HRTX remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .

However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been unchanged by 0%, while EPS estimates have been unchanged by 0%. For the upcoming Q4 2025, revenue estimates have been adjusted unchanged by 0%. These revisions correlate with a -14.2% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in HRTX long-term fundamentals.

The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

RevenueEPS

Currency: USD

Revenue Estimate-:0

EPS Estimate-:0

—

Stock Price0

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Revenue Estimates for Q4 2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-14.20%

In Past 3 Month

No data

Earnings Surprise Analysis

Revenue

EPS

AI Analysis

Earnings Reaction

The chart below shows how HRTX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HRTX sees a 11.4% change in stock price 10 days leading up to the earnings, and a 15.82% change 10 days following the report. On the earnings day itself, the stock moves by -2.73%. This data can give you a slight idea of what to expect for the next quarter's release.

For example, in MAR/2026, the stock changed 3.28% on the day following the earnings release and then changed by 3.28% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

People Also Watch

Frequently Asked Questions

What were the key highlights of HRTX's latest earnings report for ?

HRTX reported its earnings on 2026-05-11, showcasing a revenue of against an estimate of 36.13M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.03 by 0%. The stock experienced a -21.05% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

How did HRTX's stock price react after the earnings release?

Following HRTX's earnings announcement on 2026-05-11, the stock price moved by -21.05% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, HRTX's stock price tends to shift by an average of 11.4% in the 10 days leading up to earnings and 15.82% in the 10 days following, providing insight into potential market.

What are the revenue and EPS estimates for HRTX for ?

For , analysts estimate HRTX's annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

How does HRTX's stock price correlate with earnings forecast revisions?

The correlation between HRTX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

What should investors expect from HRTX's next earnings report?

Based on historical trends, HRTX's stock price typically moves by 11.4% in the 10 days before its earnings and 15.82% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

What is the sentiment in Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Summary?

The earnings call reflects mixed sentiment. While Acute Care products show strong growth and market expansion plans are promising, challenges such as competitive pressures in oncology, temporary gross margin issues, and weather-related disruptions impact overall performance. The Q&A session reveals management's proactive strategies but also highlights uncertainties, particularly regarding the Baxter settlement. The financial guidance indicates potential recovery, but the negative EBITDA and current market conditions suggest a neutral outlook for stock price movement over the next two weeks.